Monday, January 7, 2013
A strong crop of early PDUFA
dates and a sense that FDA is more navigable have given money managers
in the U.S. and Europe a positive outlook for 2013, which they hope will
be another year with a high number of approvals.
That will make the year more
about launches than data, but even so, optimism remains. Indeed, the strength
of the upcoming products means for the first time since 2010, investors no
longer view biotech launches as automatic shorts.